Injectable Drug Delivery Devices - Market Insights, Competitive Landscape, and Market Forecast - 2030

Injectable Drug Delivery Devices Market Dynamics:

According to the data cited by the World Health Organization 2022, worldwide around 2.26 million cases of breast, 2.21 million cases of lung, 1.93 million cases of colon and rectum, 1.41 million cases of prostate, and 1.09 million cases of stomach cancer were reported in 2020.

As per statistics by the IDF Diabetes Atlas (2023), 537 million adults were living with diabetes in 2021. This number is predicted to rise to 643 million by 2030 and 783 million by 2045.

As per the data provided by British Heart Foundation 2022, worldwide around 550 million which stands for 1 in 14 people were living with heart and circulatory diseases in 2019 and this includes about 290 million women and around 260 million men.

Hence, due to the rise in incidences of cancer, diabetes, and cardiovascular disorders among other chronic conditions, there will be a rise observed in the chemotherapy and insulin delivery procedures and hence the increase in the injectable drug delivery market.

However, certain side effects caused due to the nanoparticles of the drug delivery system and the high cost associated with advanced injectable drug delivery devices are expected to limit the market growth over the forecast period.

Injectable Drug Delivery Devices Market Segment Analysis:

Injectable Drug Delivery Devices Market by Product Type (Self-Injectors, Needle-Free, Auto Injectors, Wearable Injectors, and Insulin Pens), Drug Loading (Prefilled Injection Devices and Fillable Injection Devices), Reusability (Reusable and Disposable), Site of Delivery (Intramuscular, Subcutaneous, and Intra Dermal), End-User (Hospitals, Specialty Clinics, and Homecare Settings), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)

In the product type segment of the Injectable Drug Delivery Devices Market, self-injectors are likely to dominate the injectable drug delivery devices market. There have been innumerable innovations and developments that have taken place in this arena. Some profound advantages offered by self-injectors are that they are extremely convenient for patient use and are available at low costs. The product is built after patient feedback to expose patients to the most adaptable devices that can cater to the high precision of drug delivery and are easy to use. The preference for this device has lately increased among patients. Overall, the advantages offered by self-injectors and the awareness among patients of self-administration will lead to a surge in the market demand for these devices.

Several technological advancements have led to an increased acceptance of self-injectors among patients. The use of liquefied gas, for instance, liquefied hydrofluoroalkane (HFA), has acted as a power source presenting several advantages over the conventional spring-based injectors. The major advantage is that it tends to offer a constant force throughout the injection. To achieve full injection, the HFA-powered autoinjectors tend to require lower peak forces when compared with the typical spring autoinjector because the force does not tend to decay. This applies lower stresses on the syringe and results in a lower variation of force during drug delivery.

In October 2019, Becton Dickinson launched the two-step disposable autoinjector BD Intevia™, a robust platform device that combines an autoinjector and pre-fillable syringe in an integrated system. The device was developed to promote patient ease of use when self-injecting. Such product development activities are going to positively impact the market growth.

Hence, due to the various advantages offered by self-injectors in contrast to other product types, there will be an increase in demand among patients for these, leading to a surge in the self-injector market.

North America is expected to dominate the overall Injectable Drug Delivery Devices Market:

Among all the regions, North America is expected to account for the largest share of the injectable drug delivery devices market. This can be attributed to the rising numbers of chronic diseases, increasing research and developments, government initiatives to increase awareness about chronic conditions, and the rise in healthcare spending are predicted to be the major influencing factors in driving the overall growth of the market over the forecast period.

As per the figures mentioned by the American Cancer Society 2021, it was estimated that 1.9 million new cancer cases have been diagnosed in the United States in 2021. Also, according to the data provided by the Centers for Disease Control and Prevention (CDC) 2021, around 1,752,735 new cases of cancer were reported in the US in 2019. As per Globocan 2021 data, there were around 61,152 new cases of leUnited Kingdomemia recorded in 2020 in the United States. As per the same source around 73, 652 cases of Non-Hodgkin lymphoma and 8,107 new cases of Hodgkin lymphoma were recorded in 2020 in the US.

The American Heart Association in 2021 projected that by 2035, more than 130 million US adults will have some type of heart disease.

Therefore, owing to the presence of a large patient pool in the country, the injectable drug delivery devices market is expected to bolster in the United States during the forecast period.

Injectable Drug Delivery Devices Market Key Players:

Some of the key market players operating in the injectable drug delivery devices market include Eli Lilly and Company, Biocon, Becton, Dickinson & Company, West Pharmaceutical Services, Inc., Johnson & Johnson, Antares Pharma, AbbVie Inc., Pfizer Inc., Mylan N.V., Vetter Pharma-Fertigung GmbH & Co.KG, Emperra GmbH, Gerresheimer AG, SCHOTT AG, Terumo Corporation and others.

Recent Developmental Activities in Injectable Drug Delivery Devices Market:

• On November 13, 2019, Stevanato and Duoject entered auto-injector collaboration for manufacturing and promoting the emergency use ‘Maverick’ auto-injector.
• On October 21, 2019, Becton Dickinson and Company, a leading global medical technology company announced the launch of BD Intevia™ 1mL two-step disposable autoinjector, a robust platform device combining autoinjector and pre-fillable syringe in one integrated system.

Key Takes Away from the Injectable Drug Delivery Devices Market Report Study

• Market size analysis for current market size (2023), and market forecast for 6 years (2024 to 2030)
• Top key product/services/technology developments, mergers, acquisitions, partnerships, and joint ventures happened for the last 3 years
• Key companies dominating the injectable drug delivery devices market.
• Various opportunities available for the other competitor in the injectable drug delivery devices market space.
• What are the top-performing segments in 2023? How these segments will perform in 2030?
• Which are the top-performing regions and countries in the current market scenario?
• Which are the regions and countries where companies should have concentrated on opportunities for market growth in the coming future?

Target Audience who can be benefited from the Injectable Drug Delivery Devices Market Report Study

• Injectable Drug Delivery Devices providers
• Research organizations and consulting companies
• Injectable Drug Delivery Devices-related organization, association, forum, and other alliances
• Government and corporate offices
• Start-up companies, venture capitalists, and private equity firms
• Distributors and Traders
• Various End-Users who want to know more about the injectable drug delivery devices market and the latest technological developments in the injectable drug delivery devices market.

Frequently Asked Questions for Injectable Drug Delivery Devices Market:

1. What are injectable drug delivery devices?

Injectable Drug Delivery devices comprise self-injectors, needle-free, auto injectors, and others. These devices help in drug delivery at targeted areas in the body. The devices tend to allow patients for easier administration of drugs without the need for any medical assistance.

2. What is the market for injectable drug delivery devices?

The injectable drug delivery devices market was valued at USD 19.63 billion in 2023, growing at a CAGR of 11.26% during the forecast period from 2024 to 2030, to reach USD 37.22 billion by 2030.

3. What are the drivers for injectable drug delivery devices?

The major drivers driving the demand for injectable drug delivery devices are the rising incidences of chronic conditions, for instance, cancer, diabetes, and cardiovascular disorders among others, an increase in the demand for self-injectors, a rise in biologics and biosimilar market and the increasing need and demand for patient compliance to treatment and the rising innovations and technological advancement in this arena.

4. What are the key players operating in global injectable drug delivery devices?

Some of the key market players operating in the injectable drug delivery devices market include Eli Lilly and Company, Biocon, Becton, Dickinson & Company, West Pharmaceutical Services, Inc., Johnson & Johnson, Antares Pharma, AbbVie Inc., Pfizer Inc., Mylan N.V., Vetter Pharma-Fertigung GmbH & Co.KG, and others.

5. What regions have the highest share in the injectable drug delivery devices market?

North America is expected to dominate the overall injectable drug delivery devices market during the forecast period, 2024 to 2030. This domination is due to the increasing numbers of chronic diseases, rising research and developments, and increasing government initiatives to improve awareness about chronic conditions and the rise in healthcare spending.


This product will be delivered within 2 business days.